甲磺酸伊马替尼联合肝动脉化疗栓塞术治疗胃肠间质瘤肝转移的疗效观察  

Therapeutic effect of TACE combined with imatinib mesylate in hepatic metastases of gastrointestinal stromal tumors

作　　者：李金鹏[1] 宋金龙[1] 

机构地区：[1]山东省医学科学院/山东省肿瘤医院外九科,济南250117

出　　处：《疑难病杂志》2012年第6期430-432,共3页Chinese Journal of Difficult and Complicated Cases

摘　　要：目的观察甲磺酸伊马替尼(格列卫)联合肝动脉化疗栓塞术(TACE)治疗胃肠间质瘤(GIST)肝转移的疗效及安全性。方法选取26例中晚期胃肠间质瘤肝转移的患者仅行TACE治疗(对照组),同时选取19例中晚期胃肠间质瘤肝转移的患者,给予格列卫口服联合TACE治疗(观察组),比较2组患者的临床疗效和生存率、中位生存期。结果观察组有效率为78.9%,明显高于对照组的69.2%(P<0.05);对照组患者1、2、3年生存率分别为69.2%、53.8%和19.2%,中位生存期1.72年;观察组患者1、2、3年生存率分别为84.2%、73.7%和47.4%,中位生存期2.10年。观察组的生存率及生存期均显著高于对照组(P<0.05)。结论格列卫联合TACE治疗晚期胃肠间质瘤肝转移疗效及安全性优于仅行TACE治疗。Objective To study the efficacy and safety of TACE combined with imatinib mesylatc in hepatic metasta- ses of gastrointestinal stromal tumors. Methods Twenty-six patients with advanced hepatic metastases of gastrointestinal stro- mal tumors were treated by single TACE （control group）, other nineteen patients were treated by imatinib mesylate combina- tion with TACE （ experimental group）. The therapeutic effect, survival rates and median survival of two groups were com- pared. Results The effective rate of the experimental group was 78.9%, significantly higher than that in the control group （69.2%, P 〈0.05）. The survival rates in 1,2 and 3 years were 69.2%, 53.8% and 19.2% ,respectively, with a median survival time of 1.72 years in the control group, and 84.2% , 73.7% and 47.4%, respectively, with a median survival time of 2.1 years in experimental group. The survival rates and median survival time in the experimental group were significantly improved than those of the control group （ P 〈 0.05）. Conclusion It suggested that the TACE combined with imatinib mesy- late was a safe and effective therapy strategies for patients with advanced hepatic metastases of gastrointestinal stromal tumors.

关 键 词：甲磺酸伊马替尼 肝动脉化疗栓塞术 胃肠间质瘤 肝转移 

分 类 号：R735[医药卫生—肿瘤]